Bethany Sensenig Sells 4,475 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Bethany Sensenig sold 4,475 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Supernus Pharmaceuticals Stock Performance

SUPN traded down $0.17 on Monday, hitting $50.69. 563,504 shares of the company were exchanged, compared to its average volume of 687,086. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The firm has a market capitalization of $2.91 billion, a P/E ratio of -149.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.71. The business’s fifty day moving average is $50.17 and its 200 day moving average is $47.95.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 30.8% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Supernus Pharmaceuticals by 1.7% during the third quarter. Arizona State Retirement System now owns 16,547 shares of the specialty pharmaceutical company’s stock worth $791,000 after buying an additional 277 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of Supernus Pharmaceuticals by 3.6% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after buying an additional 290 shares during the period. Finally, SummitTX Capital L.P. lifted its stake in shares of Supernus Pharmaceuticals by 2.7% during the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after buying an additional 303 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a report on Friday, December 19th. Bank of America began coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $61.60.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.